Allan Stahl
Cardiovascular Disease · Las Vegas, NVNPI 1528017308
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $12,317 of the $16,434 with a category attached, or 74.9%. Pharmacosmos Therapeutics Inc. accounts for 76.1% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2024 at $13,342 and has fallen 90.9% since, to $1,218 in 2025.
Across 157 payments — averaging $104.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacosmos Therapeutics Inc.$13K
- Novartis$899
- Merck$420
- Chiesi USA, Inc.$300
- Abbott$276
- Boston Scientific$243
- plus $2K from 27 others
What the payments were for
- Consulting fees$1251%
- Speaking & faculty fees$3002%
- Travel & lodging$12,31775%
- Food & beverage$3,59222%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacosmos Therapeutics Inc. | 2 | $12,507 |
| Novartis | 44 | $899 |
| Merck | 21 | $420 |
| Chiesi USA, Inc. | 1 | $300 |
| Abbott | 3 | $276 |
| Boston Scientific | 10 | $243 |
| Pfizer | 8 | $168 |
| AstraZeneca | 4 | $152 |
| Alnylam Pharmaceuticals Inc. | 7 | $151 |
| Bayer | 1 | $125 |
| Novo Nordisk | 6 | $124 |
| Johnson & Johnson | 6 | $123 |
| Arbor Pharmaceuticals, Inc. | 7 | $102 |
| Kestra Medical Technology Services, Inc. | 1 | $102 |
| Sanofi-aventis U.S. LLC | 4 | $90 |
| Edwards Lifesciences | 3 | $84 |
| Amgen | 5 | $76 |
| Kowa Pharmaceuticals America, Inc. | 3 | $68 |
| Boehringer Ingelheim | 3 | $64 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Cvrx, Inc. | 2 | $52 |
| Lexicon Pharmaceuticals, Inc. | 2 | $33 |
| Impulse Dynamics (USA) Inc. | 1 | $26 |
| Roche Diagnostics Corporation | 1 | $25 |
| Lundbeck LLC | 1 | $25 |
| Roche Molecular Systems, Inc. | 1 | $24 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Abiomed | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Medtronic | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monoferric$12,507
- JUXTAPID$300
- CARDIOMEMS$172
- Adempas$125
- Assure WCD$102
How this compares
$16,434 in reported general payments places this provider in the 80th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 62 | $78,317 |
| XareltoRivaroxaban | 64 | $73,019 |
| EntrestoSacubitril/Valsartan | 19 | $37,032 |
| Repatha SureclickEvolocumab | 19 | $13,255 |
| Niacin ErNiacin | 15 | $2,385 |
| Nitroglycerin PatchNitroglycerin | 33 | $2,183 |
| Rosuvastatin Calcium | 108 | $1,622 |
| Nebivolol Hcl | 28 | $1,421 |
| Ranolazine ErRanolazine | 15 | $1,346 |
| Valsartan | 44 | $1,325 |
| Omega-3 Acid Ethyl Esters | 15 | $1,241 |
| Bumetanide | 36 | $1,073 |
| Atorvastatin Calcium | 174 | $1,006 |
| Ezetimibe | 46 | $971 |
| Acebutolol Hcl | 20 | $828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $168 | $78,31762 claims |
| Johnson & JohnsonXarelto | $123 | $73,01964 claims |
| NovartisEntresto | $899 | $37,03219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.